The enhancement of Nrf2 transcription with sulforaphane or melatonin could benefit patients with “LONG COVID” (Post-Acute Sequelae of SARS-CoV-2 or Post-COVID-Syndrome), a significant proportion (approximately 40%) of individuals with COVID-19 experiencing a variety of symptoms (loss of smell and/or taste, fatigue, cough, aching pain, “brain fog,” insomnia, shortness of breath, and tachycardia) after 12 weeks (Jarrott et al., 2022; Ordonez et al., 2022). Here, NFE2L2 is linked to COVID-19.